Zoetis Stock News

Capital Asset Advisory Services LLC raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 12.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,792 shares of the companys stock after acquiring an additional 514 shares during the period. Capital Asset []

Appleton Partners Inc. MA increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 0.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 98,608 shares of the companys stock after buying an additional 131 shares during the quarter. Zoetis comprises []

Professor Tim Spector, lead scientist of the ZOE study has expressed his concerns as as cases are rising but there is a spike amongst younger children. Latest data from the The post Expert raises concerns as cases among children are steadily rising and explains how we can best protect ourselves this Christmas appeared first on London Business News | Londonlovesbusiness.com .

CHRISTMAS is at risk unless people get their Covid booster jabs, experts say. Cases are on the rise once again, according to study, and many people will be unaware they are infected because the disease is being masked by cold symptoms. The ZOE COVID Study estimates 76,728 new people are getting symptomatic Covid in the […]

Aries Wealth Management reduced its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 7.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,038 shares of the company’s stock after selling 84 shares during the quarter. Aries Wealth Management’s holdings in Zoetis […]

The companion animal diagnostics market was valued at US$ 2,031.62 million in2019 and is projected to reach US$ 2,684.86 million by 2027; it is expected to grow at a CAGR of 4.1%from 2020to 2027. Zoetis Inc., IDEXX laboratories, Inc, Thermo Fisher

Private Capital Group LLC grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 4.0% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 2,015 shares of the company’s stock after buying an additional 78 shares during the period. Private Capital Group LLC’s holdings in Zoetis were worth $391,000 at the end of the […]

Rosenberg Matthew Hamilton lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 20.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 331 shares of the companys stock after buying an additional 56 shares during the quarter. Rosenberg Matthew Hamiltons holdings in Zoetis []

A LAST TECH has revealed to her followers how she gets her full and fluttery lashes without extensions. Zoe Hill, 22, is a lash technician and make-up artist based in Surrey, and shared her lash routine on her TikTok account, zoeilanahill2, where it has been viewed over 400k times. Zoe is often asked by users []

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the Equine Healthcare market segments which include products, applications, and competitor

Contravisory Investment Management Inc. cut its holdings in Zoetis Inc. (NYSE:ZTS) by 3.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 33,464 shares of the companys stock after selling 1,165 shares during the period. Zoetis accounts for 2.0% of Contravisory Investment Management []

Wall Street brokerages expect Zoetis Inc. (NYSE:ZTS) to report earnings per share (EPS) of $0.98 for the current quarter, according to Zacks. Five analysts have made estimates for Zoetis earnings, with estimates ranging from $0.95 to $1.09. Zoetis reported earnings of $0.91 per share during the same quarter last year, which would suggest a positive []

Zoetis Inc. found using ticker (ZTS) now have 11 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 258 and 184 and has a mean target at 236.55. With the stocks previous close at 225.54 this would indicate that there is a potential upside of 4.9%. The 50 day moving average now sits at 206.75 and the 200 day MA is 185.9. The company has a market cap of $107,130m. Company Website: /> [stock_market_widget type="chart" symbol="ZTS" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms.

CVA Family Office LLC reduced its holdings in Zoetis Inc. (NYSE:ZTS) by 80.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 235 shares of the companys stock after selling 974 shares during the period. CVA Family Office LLCs holdings in Zoetis were worth []

Pensionfund DSM Netherlands trimmed its stake in Zoetis Inc. (NYSE:ZTS) by 70.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,100 shares of the companys stock after selling 17,100 shares during the period. Pensionfund DSM Netherlands holdings in Zoetis were []